Pfizer Critic Boosts AstraZeneca Ties Amid Talk Of New Bid
The high-profile British fund manager who publicly opposed Pfizer Inc.'s failed $118 billion campaign to merge with AstraZeneca PLC on Monday revealed a sizable stake in the erstwhile target ahead of...To view the full article, register now.
Already a subscriber? Click here to view full article